← Back to headlines
China Approves Subcutaneous Leqembi for Early Alzheimer's Treatment
Chinese regulators have granted approval for the subcutaneous injection form of lecanemab (Leqembi) to serve as an initial therapy for patients diagnosed with early-stage Alzheimer's disease.
3 Sept, 04:00 — 3 Sept, 04:00
